790695-49-7

Upstream product

• 320-32-1 4-hydroxy-2-(trifluoromethyl)benzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 1260805-25-1 C₁₆H₁₃F₃O₃ 

Downstream Products

• 1163281-01-3 methyl 4-hydroxy-5-nitro-2-(trifluoromethyl)benzoate 
• 790695-56-6 4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoic acid 
• 790695-54-4 methyl 4-{[(2S)-2-hydroxypropyl]oxy}-2-(trifluoromethyl)benzoate 
• 957207-41-9 4-(trifluoromethanesulfonyloxy)-2-(trifluoromethyl)benzoic acid methyl ester 
• 1040724-02-4 4-cyclopropylmethoxy-2-trifluoromethyl-benzoic acid methyl ester 
• 790695-53-3 methyl 4-{[(2S)-2-acetoxypropyl]oxy}-2-(trifluoromethyl)benzoate 
• 790695-50-0 methyl 4-(2-oxopropoxy)-2-(trifluoromethyl)benzoate 

Relevant academic research and scientific papers

BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1

The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are l

Soluble Guanylate Cyclase Activators

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

4,4-DIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVE OR SALT THEREOF

A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided.